Cencora, Inc. $COR Shares Bought by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. raised its stake in shares of Cencora, Inc. (NYSE:COR) by 8.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 93,319 shares of the company’s stock after buying an additional 7,371 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Cencora were worth $28,033,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in COR. BlackRock Inc. purchased a new stake in shares of Cencora in the second quarter worth $5,154,136,000. Bank of America Corp DE lifted its stake in shares of Cencora by 6.9% in the first quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock worth $1,300,033,000 after buying an additional 267,318 shares in the last quarter. Amundi grew its holdings in shares of Cencora by 43.5% during the second quarter. Amundi now owns 2,229,326 shares of the company’s stock valued at $630,855,000 after buying an additional 676,066 shares during the last quarter. Carmignac Gestion grew its holdings in shares of Cencora by 58.7% during the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after buying an additional 646,112 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Cencora during the second quarter valued at approximately $483,772,000. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

Shares of NYSE COR opened at $359.12 on Friday. The firm’s 50-day moving average price is $327.12 and its 200-day moving average price is $317.20. The company has a quick ratio of 0.59, a current ratio of 0.94 and a debt-to-equity ratio of 3.01. The company has a market cap of $68.53 billion, a PE ratio of 20.04, a PEG ratio of 1.81 and a beta of 0.58. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, beating the consensus estimate of $4.58 by $0.08. The firm had revenue of $88.35 billion during the quarter, compared to analysts’ expectations of $87.95 billion. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the company earned $3.84 earnings per share. As a group, analysts anticipate that Cencora, Inc. will post 19.58 EPS for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be given a $0.66 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, November 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is presently 13.39%.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

COR has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $390.00 to $413.00 and gave the stock an “overweight” rating in a report on Tuesday. Evercore reaffirmed an “outperform” rating and issued a $350.00 price objective (up from $330.00) on shares of Cencora in a research report on Thursday, August 6th. Robert W. Baird increased their target price on Cencora from $373.00 to $375.00 and gave the company an “outperform” rating in a research note on Thursday, October 22nd. Argus lifted their target price on Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a report on Tuesday, October 20th. Finally, Morgan Stanley boosted their price target on Cencora from $346.00 to $377.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Twelve equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $368.14.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.